Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims
This article was originally published in The Tan Sheet
Executive SummaryElements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker
You may also be interested in...
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.